A CCR5 Inhibitor Shows Promise
Infectious Diseases Summary and Comment
Vicriviroc, an investigational CCR5 inhibitor, demonstrates excellent HIV suppression in treatment-experienced patients.
By Daniel J. Diekema, MD, MS
July 18, 2007
Covering:
Gulick RM et al., J Infect Dis 2007 Jul 15; 196:304-12
Limitations of Rapid Testing
HIV/AIDS Clinical Care Summary and Comment
Free
The performance characteristics of a sequential rapid HIV-testing algorithm were poorer than anticipated in a Ugandan study, perhaps due to false-positive results from tests with "faint bands."
By Rochelle P. Walensky, MD, MPH
July 16, 2007
Covering:
Gray RH et al., BMJ 2007 Jun 1
Neurosyphilis: Neither Gone nor Forgotten
As William Osler said: "Know syphilis in all its manifestations and relations, and all things clinical will be added unto you."
By Jodie Dionne-Odom, MD
July 16, 2007
Covering:
Centers for Disease Control and Prevention (CDC)., MMWR Morb Mortal Wkly Rep 2007 Jun 29; 56:625-8
Might Treating Asymptomatic Bacterial Vaginosis Prevent Sexually Transmitted Infections?
General Medicine Summary and Comment
Treatment and prophylaxis resulted in significantly fewer new cases of chlamydia.
By Robert W. Rebar, MD
July 3, 2007
Covering:
Schwebke JR and Desmond R., Am J Obstet Gynecol 2007 Jun; 196:517.e1-6
Complications of Smallpox Vaccination
Dermatology Summary and Comment
Free
Direct contact with the recently vaccinated can cause vaccinia infections in others.
By Jan V. Hirschmann, MD
June 29, 2007
Covering:
Centers for Disease Control and Prevention (CDC)., MMWR Morb Mortal Wkly Rep 2007 May 4; 56:417-9
Centers for Disease Control and Prevention (CDC)., MMWR Morb Mortal Wkly Rep 2007 May 18; 56:478-81
USPSTF Recommends Screening for Chlamydial Infection in Women at Risk
General Medicine Clinical Practice Guideline Watch
Young sexually active or pregnant women should be screened, but older women without risk factors should not; the evidence is insufficient to assess screening for men.
By Richard Saitz, MD, MPH, FACP, FASAM
June 28, 2007
Covering:
U.S. Preventive Services Task Force., Ann Intern Med 2007 Jul 17; 147:128-33
Meyers DS et al., Ann Intern Med 2007 Jul 17; 147:136-43
Outcomes of TB Treatment in HIV-Infected Patients
Infectious Diseases Summary and Comment
Relapse rates were significantly higher in TB patients with HIV infection than in those without such infection.
By Neil M. Ampel, MD
June 20, 2007
Covering:
Nahid P et al., Am J Respir Crit Care Med 2007 Jun 1; 175:1199-206
Fluoroquinolones No Longer Recommended for Empirical Gonorrhea Treatment
Infectious Diseases Summary and Comment
Because of increasing gonococcal resistance to fluoroquinolones, these drugs should not be used for initial treatment of gonorrhea.
By Stephen G. Baum, MD
June 6, 2007
Covering:
Centers for Disease Control and Prevention (CDC)., MMWR Morb Mortal Wkly Rep 2007 Apr 13; 56:332-6
Sexual Transmission of Hepatitis C Virus
Infectious Diseases Summary and Comment
An outbreak of hepatitis C infection among HIV-infected men who have sex with men suggests sexual transmission of the virus.
By Rajesh T. Gandhi, MD
June 6, 2007
Covering:
Danta M et al., AIDS 2007 May 11; 21:983-91
Survival Benefits of Retention in HIV Care
HIV/AIDS Clinical Care Summary and Comment
Free
Quarterly outpatient visits for HIV care improve the chances of long-term survival.
By Rochelle P. Walensky, MD, MPH
June 4, 2007
Covering:
Giordano TP et al., Clin Infect Dis 2007 Jun 1; 44:1493-9
Cheever LW., Clin Infect Dis 2007 Jun 1; 44:1500-2
New Estimates of Post-ART Survival
Clinicians and patients will soon be able to calculate 5-year survival rates online.
By Paul E. Sax, MD
June 4, 2007
Covering:
The Antiretroviral Therapy (ART) Cohort Collaboration., AIDS 2007 May 31; 21:1185-97
Can ART Reduce Sexual Transmission of HIV Among MSM?
The potential reduction in secondary HIV transmission may be offset by the longer duration of infectiousness.
By Carlos del Rio, MD
June 4, 2007
Covering:
McCormick AW et al., Clin Infect Dis 2007 Apr 15; 44:1115-22
HIV and STD Screening in the ED
Emergency Medicine Summary and Comment
A combined ED-based screening program is feasible.
By Richard D. Zane, MD, FAAEM
June 1, 2007
Covering:
Silva A et al., Ann Emerg Med 2007 May; 49:564-72
HPV Vaccine Prevents Precancerous Vulvovaginal Lesions
General Medicine Summary and Comment
No women who completed the full vaccine protocol developed lesions related to an HPV type to which they were previously susceptible.
By Bruce Soloway, MD
May 31, 2007
Covering:
Joura EA et al., Lancet 2007 May 19; 369:1693-702
Could Early and Continuous HIV Therapy Achieve Eradication?
Infectious Diseases Summary and Comment
Free
The decay rate of the HIV reservoir in patients treated early in infection raises the question of whether eradication is possible with prolonged continuous therapy.
By Daniel J. Diekema, MD, MS
May 23, 2007
Covering:
Chun TW et al., J Infect Dis 2007 Jun 15; 195:1762-4
Margolis DM and Archin NM., J Infect Dis 2007 Jun 15; 195:1734-6
HPV Vaccination Update: An Important Hurdle
Women's Health Summary and Comment
Free
The HPV vaccine was highly effective against anogenital and cervical lesions in women with no previous vaccine-specific HPV exposure.
By Sandra Ann Carson, MD
May 17, 2007
Covering:
Garland SM et al., N Engl J Med 2007 May 10; 356:1928-43
The FUTURE II Study Group., N Engl J Med 2007 May 10; 356:1915-27
Sawaya GF and Smith-McCune K., N Engl J Med 2007 May 10; 356:1991-3
Don’t Treat Gonococcal Infections with Fluoroquinolones
Women's Health Practice Watch
The rising prevalence of fluoroquinolone resistance has prompted revision of CDC treatment guidelines.
By Diane E. Judge, APN/CNP
May 17, 2007
Covering:
Centers for Disease Control and Prevention (CDC)., MMWR Morb Mortal Wkly Rep 2007 Apr 13; 56:332-6
Fluoroquinolones No Longer Recommended to Treat Gonorrhea
Emergency Medicine Summary and Comment
Free
Due to growing resistance of <$EMPH_O>N. gonorrhoeae<$EMPH_C> to fluoroquinolones, the CDC now recommends cephalosporins to treat gonorrhea and related infections.
By Diane M. Birnbaumer, MD, FACEP
May 11, 2007
Covering:
Centers for Disease Control and Prevention (CDC)., MMWR Morb Mortal Wkly Rep 2007 Apr 13; 56:332-6
HPV Vaccination: Data at Last
General Medicine Summary and Comment
Free
The short-term results of a three-dose immunization schedule are impressive for many recipients. As for the long term: Still unclear.
By Abigail Zuger, MD
May 9, 2007
Covering:
Garland SM et al., N Engl J Med 2007 May 10; 356:1928-43
The FUTURE II Study Group., N Engl J Med 2007 May 10; 356:1915-27
Sawaya GF and Smith-McCune K., N Engl J Med 2007 May 10; 356:1991-3
Charo RA., N Engl J Med 2007 May 10; 356:1905-8
Agosti JM and Goldie SJ., N Engl J Med 2007 May 10; 356:1908-10
HPV-16 and Oropharyngeal Cancers
Dermatology Summary and Comment
Free
HPV infection and multiple sex partners were associated with an increased risk for oropharyngeal cancer.
By Lowell A. Goldsmith, MD, MPH
May 9, 2007
Covering:
D’Souza G et al., N Engl J Med 2007 May 10; 356:1944-56
The HPV Vaccine and Cervical Neoplasia: Not Just for Warts Anymore
Dermatology Summary and Comment
Free
Widespread immunization against HPV will reduce rates of both cervical cancer and genital warts.
By Craig A. Elmets, MD
May 9, 2007
Covering:
The FUTURE II Study Group., N Engl J Med 2007 May 10; 356:1915-27
More Than an Ounce of Prevention for HPV
Dermatology Summary and Comment
A safe and effective HPV vaccine means reduced risk for associated disease now and a hope for future vaccines.
By Craig A. Elmets, MD
May 9, 2007
Covering:
Garland SM et al., N Engl J Med 2007 May 10; 356:1928-43
Efficacy and Safety of the Quadrivalent HPV Vaccine
Infectious Diseases Summary and Comment
Free
Two randomized controlled trials provide an additional year of follow-up.
By Richard T. Ellison III, MD
May 9, 2007
Covering:
Garland SM et al., N Engl J Med 2007 May 10; 356:1928-43
The FUTURE II Study Group., N Engl J Med 2007 May 10; 356:1915-27
Sawaya GF and Smith-McCune K., N Engl J Med 2007 May 10; 356:1991-3
HPV-16 and Oropharyngeal Cancer
Infectious Diseases Summary and Comment
Free
HPV-16 infection was shown to be an independent risk factor for oropharyngeal squamous-cell carcinoma.
By Richard T. Ellison III, MD
May 9, 2007
Covering:
D’Souza G et al., N Engl J Med 2007 May 10; 356:1944-56
HIV Integrase-Inhibitor Advances
Infectious Diseases Summary and Comment
Raltegravir, the first drug in this new class of antiretroviral agents, shows promise in patients infected with multidrug-resistant virus.
By Rajesh T. Gandhi, MD
May 9, 2007
Covering:
Grinsztejn B et al., Lancet 2007 Apr 14; 369:1261-9
